A5001022411- Prostate Cancer Treatment and Research
- Multiple Myeloma Research and Treatments
- Breast Cancer Treatment Studies
- Prostate Cancer Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Breast Lesions and Carcinomas
- Radiopharmaceutical Chemistry and Applications
- Advanced Radiotherapy Techniques
- Lymphoma Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- Medical Imaging Techniques and Applications
- Breast Implant and Reconstruction
- Intraperitoneal and Appendiceal Malignancies
- HER2/EGFR in Cancer Research
- Sarcoma Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Colorectal Cancer Surgical Treatments
- Head and Neck Cancer Studies
- Cancer Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Epigenetics and DNA Methylation
Inserm
2016-2025
Centre National de la Recherche Scientifique
2016-2025
Institut de Cancérologie de l'Ouest
2016-2025
Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers
2015-2025
Institut Génétique Nantes Atlantique
2013-2024
Nantes Université
2014-2024
Université d'Angers
2017-2020
Roche (France)
2020
Centre Hospitalier René-Dubos
2001-2017
Institut Bergonié
2007-2017
Cytogenetics is an important prognostic parameter in multiple myeloma (MM). Patients presenting with either t(4;14) or del(17p) are known to have a short event-free survival (EFS) and overall (OS). Some preliminary data suggest that bortezomib able overcome these parameters.A series of 507 patients newly diagnosed MM who received four cycles bortezomib-dexamethasone induction therapy before high-dose melphalan were analyzed for both del(17p).We found remain parameters, even the context...
After unsuccessful surgery, medullary thyroid carcinoma (MTC) may be fatal or remain stable for decades, and precise survival predictors are needed.This study assesses the prognostic value of calcitonin carcinoembryonic antigen (CEA) doubling-times (DT).This is a retrospective on 65 MTC patients from 2.9-29.5 yr after surgery.Data registered in database French Neuroendocrine Tumor Group were analyzed anonymously.All had abnormal levels total thyroidectomy bilateral lymph node...
Survival of patients with multiple myeloma is highly heterogeneous, from periods a few weeks to more than 10 years. We used gene expression profiles cells obtained at diagnosis identify broadly applicable prognostic markers.In training set 182 patients, we supervised methods individual genes associated length survival. A survival model was built these genes. The validity our assessed in test 68 and three independent cohorts comprising 853 myeloma.The 15 strongest the were calculate risk...
Triple-negative breast cancers need to be refined in order identify therapeutic subgroups of patients.We conducted an unsupervised analysis microarray gene-expression profiles 107 triple-negative cancer patients and undertook robust functional annotation the molecular entities found by means numerous approaches including immunohistochemistry signatures. A external cohort (n=87) was used for validation.Fuzzy clustering separated tumours into three clusters: C1 (22.4%), C2 (44.9%) C3 (32.7%)....
Chromosomal aberrations are a hallmark of multiple myeloma but their global prognostic impact is largely unknown.We performed genome-wide analysis malignant plasma cells from 192 newly diagnosed patients with using high-density, single-nucleotide polymorphism (SNP) arrays to identify genetic lesions associated prognosis.Our analyses revealed deletions and amplifications in 98% patients. Amplifications 1q 1p, 12p, 14q, 16q, 22q were the most frequent adverse prognosis, whereas recurrent...
We recently developed a user-friendly web-based application called bc-GenExMiner (http://bcgenex.centregauducheau.fr), which offered the possibility to evaluate prognostic informativity of genes in breast cancer by means ‘prognostic module’. In this study, we develop new module ‘correlation module’, includes three kinds gene expression correlation analyses. The first one computes coefficient between 2 or more (up 10) chosen genes. second produces two lists that are most correlated...
Purpose In multiple myeloma, many prognostic parameters have been proposed. However, all of these predict shorter survival. To identify patients with a longer life expectancy, we updated the data treated in IFM (Intergroupe Francophone du Myelome) 99-02 and 99-04 trials. Patients Methods A series 520 was analyzed. Median follow-up 90.5 months. perform comprehensive analysis major factors, reanalyzed for 1q gains [in addition to updating del(13), t(4;14), del(17p) analyses]. Results It...
This study aimed to assess prospectively the efficacy of sequential [18F]fluorodeoxyglucose positron emission tomography (FDG PET) evaluate early response neoadjuvant chemotherapy in stage II and III breast cancer patients.Images were acquired with a PET/computed scanner 64 patients after administration FDG (5 MBq/kg) at baseline first, second, third, sixth course chemotherapy. Ultrasound mammography used tumor size. Decrease standardized uptake value (SUV) PET was compared pathologic...
To determine the detection rate, false-negative and accuracy of sentinel lymph node (SLN) after neoadjuvant chemotherapy (NAC) for advanced breast cancer.A prospective multicentric study was initiated to evaluate results SLN biopsy with combined method NAC large operable cancer.From September 2003 March 2007, 195 patients enrolled from 12 institutions were found suitable evaluation. The rate 90% (176 patients), 11.5% (six 52 patients). Patients without axillary palpable nodes (N0) before had...
No effective therapy is currently available for the management of patients with metastatic medullary thyroid carcinoma (MTC). The efficacy pretargeted radioimmunotherapy (pRAIT) bispecific monoclonal antibody (BsMAb) and a iodine-131 (131I) -labeled bivalent hapten evaluated.Twenty-nine advanced, progressive MTC, as documented by short serum calcitonin doubling times (Ct DTs), received an anti-carcinoembryonic antigen (CEA)/anti-diethylenetriamine pentaacetic acid (DTPA) -indium BsMAb,...
Deletion of the 17p13 chromosomal region [del(17p)] is associated with a poor outcome in multiple myeloma. Most studies have targeted TP53 gene for deletion analyses, although no study showed that this target. In order to address issue, we sequenced 92 patients myeloma at diagnosis, 54 del(17p) and 38 lacking del(17p). At least one mutation was found 20 patients, all them presenting The analysis location virtually occurred highly conserved domains involved DNA-protein interactions....
Chromosomal abnormalities, especially t(4;14) and del(17p), are major prognostic factors in patients with multiple myeloma (MM). However, this has been demonstrated age < 66 years treated intensive approaches. The goal of study was to address issue elderly conventional-dose chemotherapy.To answer important question, we retrospectively analyzed a series 1,890 (median age, 72 years; range, 94 years), including 1,095 updated data on treatment modalities survival.This large first showed that the...
Triple-negative breast cancers (TNBC) lacking estrogen and progesterone receptors HER2 amplification have a relatively high risk of metastatic dissemination, but the mechanistic basis for this is not understood. Here, we report that serum levels CD95 ligand (CD95L) are higher in patients with TNBC than other cancer. Metalloprotease-mediated cleavage CD95L expressed by endothelial cells surrounding tumors generates gradient promotes cell motility due to formation an unconventional...
The prognosis of medullary thyroid carcinoma (MTC) varies from long- to short-term survival based on such prognostic factors as serum calcitonin and carcinoembryonic antigen (CEA) doubling times (DTs). This prospective phase II multicenter trial evaluated the efficacy safety anti-CEA pretargeted radioimmunotherapy (pRAIT) in rapidly progressing metastatic MTC patients also how biomarker DTs correlate with clinical outcome. <b>Methods:</b> From June 2004 January 2008, 42 were treated ×...